APA

Reckamp K. L., Gardner B. K., Figlin R. A., Elashoff D., Krysan K., Dohadwala M., Mao J., Sharma S., Inge L., Rajasekaran A. & Dubinett S. M. (20080416). Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chicago

Reckamp Karen L, Gardner Brian K, Figlin Robert A, Elashoff David, Krysan Kostyantyn, Dohadwala Mariam, Mao Jenny, Sharma Sherven, Inge Landon, Rajasekaran Ayyappan and Dubinett Steven M. 20080416. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harvard

Reckamp K. L., Gardner B. K., Figlin R. A., Elashoff D., Krysan K., Dohadwala M., Mao J., Sharma S., Inge L., Rajasekaran A. and Dubinett S. M. (20080416). Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MLA

Reckamp Karen L, Gardner Brian K, Figlin Robert A, Elashoff David, Krysan Kostyantyn, Dohadwala Mariam, Mao Jenny, Sharma Sherven, Inge Landon, Rajasekaran Ayyappan and Dubinett Steven M. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 20080416.